Remove 2022 Remove Generic Medicine Remove Vaccines
article thumbnail

STAT+: ‘Like playing the lottery’: A mixed picture for laid-off life sciences workers in Massachusetts

STAT

The state’s biotech scene   exploded in the mid-2010s and early in the pandemic as exuberant investors disregarded the high failure rate in drug development and bet on buzzy technologies such as gene editing and messenger RNA vaccines. But the   drumbeat of layoffs in 2022   has only grown louder this year.

Vaccines 313
article thumbnail

EMA human medicines committee (CHMP) highlights, September 2022

European Pharmaceutical Review

Biosimilar medicine Ximluci (ranibizumab) for the treatment of neovascular age-related macular degeneration, a progressive retinal macular disease, causing gradual vision impairment, mainly in the elderly population. Adapted vaccines Comirnaty Original/Omicron BA.1 Adapted vaccines Comirnaty Original/Omicron BA.1 Safety update.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EMA human medicines committee (CHMP) highlights, November 2022

European Pharmaceutical Review

Four medicines recommended for approval in the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP)’s latest meeting included a biosimilar for osteoporosis and a novel COVID-19 vaccine. Read highlights from the CHMP’s September 2022 meeting. COVID-19 update.

article thumbnail

CHMP meeting highlights – December 2022

European Pharmaceutical Review

A generic medicine, Diethyl fumarate Accord (dimethyl fumarate), received a positive opinion for the treatment of multiple sclerosis (MS), a chronic disease affecting the central nervous system. The committee recommended to extend the use of original Spikevax vaccine and Spikevax bivalent Original/Omicron BA.1 COVID-19 update.

article thumbnail

Vaccine equity: how the pandemic demonstrated global health inequality

pharmaphorum

With the rapid onset of the pandemic, the race to develop a viable vaccine quickly became a race to secure access to the developed vaccines. In this article, Ben Hargreaves examines how wealth determined the winners and what is now underway to help lower-income countries gain access to the available vaccines.

article thumbnail

CHMP meeting highlights – March 2023

European Pharmaceutical Review

It is the eighth vaccine recommended in the European Union (EU) for COVID-19. CHMP’s January 2023 meeting highlights… Read the EMA’s human medicines highlights 2022 report. The committee adopted a positive opinion for Briumvi (ublituximab) for relapsing multiple sclerosis (MS).

article thumbnail

Waters, as a strategic partner to the pharma industry, can help India become a world leader in biosimilars

Express Pharma

Many millions of people are vaccinated against COVID-19, thanks to a messenger RNA (mRNA) encapsulated within a lipid nanoparticle. India is known as the ‘Pharmacy of the World’, as the generic medicine supplier for over 200 countries, both developed and emerging markets. How poised are you to leverage them?